// STATE LEGISLATION TRACKER

Florida SB 966: Outsourcing Facilities

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Florida
Bill: SB 966
Session: 2026
Filed: 2025-12-18
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Florida SB966 would have created a state permit system for FDA-registered outsourcing facilities and reduced duplicative Florida licensing for covered 503B-style compounding activities. It could have made large-scale sterile/non-patient-specific compounding oversight clearer, but it died in committee and does not change current peptide access.

Key Points

No current legal change because the bill failed
Would have affected 503B outsourcing facilities, not office prescribing rules
Could have reduced duplicate state permitting for covered compounders
Does not appear to expand telehealth or NP/naturopath scope
No obvious change to controlled-substance or PDMP rules

What to Watch For

✓

Opportunity A similar future bill could make Florida 503B permitting clearer and reduce compliance friction for outsourcing facilities.

Concern Permit rules could still add costs or paperwork for facilities that supply compounded products.

Note This appears focused on facility regulation, not patient-level access to compounded peptides.

Where the Bill Stands

The bill died in the Senate Health Policy committee on March 13, 2026, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws